Por: RTTNews Health June 26, 2023
Pfizer Inc. () announced its decision to continue to progress one oral late-stage glucagon-like peptide-1 receptor agonist candidate toward further clinical development for the potential treatment of adults with obesity and Type 2 diabetes mellitus. The company will continue advancing the clinical program for danuglipron, subject to results from the ongoing Phase 2 trial, and discontinue the clinical development of lotiglipron. The company said... + full article
Portland Press Herald USA World June 27, 2023
Struggling to recover from waning coronavirus vaccine demand, Pfizer is racing to catch up with Novo Nordisk and Eli Lilly in an obesity-treatment market. Bloomberg photo by Stephanie Keith Pfizer shares fell after the company halted early development of an oral drug for weight... + más
Obesity in 2035 could be just as costly as COVID in 2020 | WPTV
Half Of Global Population Will Be Overweight In 12 Years: Study | RTTNews
MarketWatch USA Business June 26, 2023
Eli Lilly’s orforglipron, another once-daily pill, achieved up to 14.7% average weight loss at 36 weeks in adults with obesity or overweight, according to data shared at the ADA conference. Pfizer , meanwhile, said Monday that it would advance its investigational pill for... + más
Woman charged in death of Kim Kardashian lookalike who got silicone injections in buttocks | Los Angeles Times
NFL, '60 Minutes,' 'Big Bang Theory' top weekly ratings | Orlando Sentinel
Time USA Science June 26, 2023
shares fell after it halted early development of an oral drug for on safety concerns, raising investor anxiety about an alternative therapy the company is still developing. The drugmaker will stop work on lotiglipron based on data from phase 1 clinical trials and lab... + más
ABC News USA Health June 07, 2023
Semaglutide (Ozempic, Wegovy) and other drugs in its class are widely known for their role in managing type 2 diabetes and suppressing appetite. They may also prove helpful one day in curbing certain addictive behaviors like alcohol use and smoking, according to... + más
What is Ozempic? Why stars risk ‘old face’ for trendy weight-loss drug | New York Post
Does Medicare cover Ozempic? | WGN-TV
ABC7 USA World June 07, 2023
The consistency that I'm hearing from all across patient groups is gain of control, whereas previously, there was a loss of control, Gitanjali Srivastava, MD, an internist and director of the obesity medicine program at Vanderbilt University Medical Center in Nashville,... + más
New York Post USA Life March 07, 2023
Popular celebrity weight-loss drugs Wegovy and Ozempic could have serious side effects, according to researchers in China. In a study set to appear in the monthly journal , researchers believe that there is an “increased risk” of intestinal obstruction when taking those... + más
What to know about prescription drugs promising weight loss | ABC News
Newsweek USA Business February 06, 2023
Pfizer's involvement with the 2023 Grammy Awards sparked speculation online, with some viewers wondering how much input the pharmaceutical company had.The annual music ceremony was held at the Crypto.com Arena in Los Angeles, California on Sunday night, with Beyoncé... + más
Here's how to watch the 2023 Grammys on iPhone, iPad, Apple TV, and more | 9to5Mac
Pfizer Is Moving Beyond Covid. Why Its Stock Is a Buy. | MarketWatch
About iurex | Privacy Policy | Disclaimer |